Mirap Distab (Mirtazapine)

Mirtazapine, the active ingredient in Mirap Distab, is a NaSSA presented as an oral dosage form for oral use. It treats major depressive disorder in adult patients. GNH USA supplies Mirap Distab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a NaSSA antidepressant used in the management of mood disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood. - Depressive episodes associated with major depressive disorder: helps alleviate insomnia and anxiety. - Treatment‑resistant depression (adjunct therapy): may enhance overall therapeutic response when combined with other agents.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation: drowsiness, especially at treatment initiation. - Increased appetite: may lead to weight gain. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headedness on standing. - Fatigue: general lack of energy.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Seizures: rare occurrence of convulsive episodes. - Hepatotoxicity: potential liver enzyme elevation. - Suicidal thoughts: emergence of suicidal ideation. - Stevens‑Johnson syndrome: severe skin reactions. - Severe neutropenia: marked decrease in neutrophil count.

Before prescribing Mirap Distab, clinicians should consider several safety measures.

- Monitor weight: patients may experience significant weight gain. - Assess sedation: increased drowsiness can affect daily activities. - Evaluate hepatic function: drug is metabolized in the liver. - Avoid abrupt discontinuation: tapering reduces withdrawal risk. - Use caution in elderly: higher fall risk due to sedation. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Linezolid or other serotonergic agents: potential serotonin syndrome. - Strong CYP2D6 inhibitors: may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - CYP3A4 inhibitors (e.g., ketoconazole): may raise drug concentration. - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Anticholinergic drugs: may exacerbate dry mouth and constipation.